Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit
C Ovid-19, Sultan Acar Sevinc, Ayse Surhan Cin, Nermin Balta Basi, Seyhan Metin, Tugba Yucel, Serkan Islamoglu, Mustafa Altinay, Haci Mustafa Ozdemir, Etfal Sisli, Hospital
SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, doi:10.14744/semb.2021.35902
is the disease caused by severe acute respira- tory syndrome coronavirus 2 (SARS-CoV-2) infection and may present in different clinical scenarios: About 80% of patients present with mild, 13.8% present with severe disease, and 6.1% with critical disease. [1] According to the guidelines published by the Ministry of Health in Turkey, patients with severe and critical disease were advised to be admitted to intensive care unit (ICU). [2] Turkey diagnosed Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19. Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients' records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir. Results: A total of 100 patients' data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9-24) days with favipiravir and 8.5 (5-12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5-15) days and 4 (3-9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001).
Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed.
References
Bhatraju, Ghassemieh, Nichols, Kim, Jerome et al., Covid-19 in critically Ill patients in the Seattle regioncase series, N Engl J Med,
doi:10.1056/NEJMoa2004500Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: An open-label control study, Engineering,
doi:10.1016/j.eng.2020.03.007Du, Chen, Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther,
doi:10.1002/cpt.1844Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA,
doi:10.1001/jama.2020.5394Ilhan, Altuntas, Optimum management of COVID-19 in the geriatric population: The need for a comprehensive assessment
Kupferschmidt, Cohen, WHO launches global megatrial of the four most promising coronavirus treatments
Mitra, Fergusson, Lloyd-Smith, Wormsbecker, Foster et al., Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series, CMAJ,
doi:10.1503/cmaj.200794Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med,
doi:10.1111/joim.13091Stringer, Puskarich, Kenes, Dickson, COVID-19: The uninvited guest in the intensive care unit -implications for pharmacotherapy, Pharmacotherapy,
doi:10.1002/phar.2394Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China, JAMA,
doi:10.1001/jama.2020.1585Yamamoto, Matsuyama, Hoshino, Yamamoto, Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro, bioRxiv,
doi:10.1101/2020.04.06.026476Zheng, Sun, Xu, Pan, Zhang et al., Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China, J Zhejiang Univ Sci B,
doi:10.1631/jzus.B2000174DOI record:
{
"DOI": "10.14744/semb.2021.35902",
"ISSN": [
"1302-7123"
],
"URL": "http://dx.doi.org/10.14744/SEMB.2021.35902",
"author": [
{
"affiliation": [],
"family": "Acar Sevinc",
"given": "Sultan",
"sequence": "first"
}
],
"container-title": "SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital",
"container-title-short": "Sisli Etfal",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
9,
22
]
],
"date-time": "2021-09-22T07:37:37Z",
"timestamp": 1632296257000
},
"deposited": {
"date-parts": [
[
2021,
9,
22
]
],
"date-time": "2021-09-22T07:37:39Z",
"timestamp": 1632296259000
},
"indexed": {
"date-parts": [
[
2022,
3,
29
]
],
"date-time": "2022-03-29T14:01:08Z",
"timestamp": 1648562468806
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2021
]
]
},
"member": "5966",
"original-title": [],
"prefix": "10.14744",
"published": {
"date-parts": [
[
2021
]
]
},
"published-online": {
"date-parts": [
[
2021
]
]
},
"published-print": {
"date-parts": [
[
2021
]
]
},
"publisher": "Kare Publishing",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://sislietfaltip.org/jvi.aspx?un=SETB-35902&volume="
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subtitle": [],
"title": "Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit",
"type": "journal-article"
}
